Netherlands· NL-87db9f8a3ef9
Tezspire, 110 mg/ml, oplossing voor injectie
A tezepelumab product containing tezepelumab, registered in Netherlands by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tezepelumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX11 (tezepelumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Tezepelumab · ATC R03DX11
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tezepelumab costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tezepelumab · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.28
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TEZEPELUMAB
- Manufacturer
- AstraZeneca AB
- Country
- Netherlands (NL)
- ATC code
- R03DX11
- ATC class
- Tezepelumab
- Defined daily dose
- 7.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1677
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tezepelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEZSPIREAstraZeneca AB, Södertälje
- United StatesTEZSPIREAmgen Inc
- SwitzerlandTezspire 110 mg/ml, Injektionslösung in einem FertigpenAstraZeneca AG
- SpainTEZSPIRE 210 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAstrazeneca Ab
- FinlandTezspireAstraZeneca AB
- FranceTEZSPIRE 210 mg, solution injectable en seringue préremplieASTRAZENECA AB
- United KingdomTezspire 210mg/1.91ml solution for injection pre-filled pensAstraZeneca UK Ltd
- IcelandTezspireAstraZeneca AB*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tezspire
- Liechtenstein · Tezspire
- Norway · Tezspire
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e7184c53-0d35-4eeb-9112-3f1a3b50bd33 GET /v1/drugs/e7184c53-0d35-4eeb-9112-3f1a3b50bd33?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tezepelumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128439",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"PROLINE, (L-)",
"WATER VOOR INJECTIE"
],
"substances": [
"TEZEPELUMAB"
],
"leaflet_url": null,
"authorised_at": "2022/09/19",
"procedure_number": "EMEA/H/C/005588",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1677",
"additional_monitoring": "Y"
}See everything about tezepelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.